Kiniksa Pharmaceuticals International, plc $KNSA Shares Newly Purchased by Sowell Financial Services LLC

Sowell Financial Services LLC bought a new stake in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 40,735 shares of the company’s stock, valued at approximately $3,039,000. Sowell Financial Services LLC owned about 0.05% of Kiniksa Pharmaceuticals International as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of KNSA. Headlands Technologies LLC purchased a new stake in Kiniksa Pharmaceuticals International during the second quarter worth about $1,161,000. OMERS ADMINISTRATION Corp bought a new stake in Kiniksa Pharmaceuticals International in the first quarter worth about $631,000. Handelsbanken Fonder AB bought a new stake in Kiniksa Pharmaceuticals International in the second quarter worth about $1,343,000. The Manufacturers Life Insurance Company boosted its stake in Kiniksa Pharmaceuticals International by 56.7% in the first quarter. The Manufacturers Life Insurance Company now owns 63,346 shares of the company’s stock valued at $3,050,000 after acquiring an additional 22,917 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its stake in Kiniksa Pharmaceuticals International by 213.5% in the first quarter. Janus Henderson Group PLC now owns 481,023 shares of the company’s stock valued at $23,197,000 after acquiring an additional 327,595 shares during the last quarter. Institutional investors own 53.95% of the company’s stock.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, CAO Michael Megna sold 4,600 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $80.30, for a total value of $369,380.00. Following the transaction, the chief accounting officer directly owned 29,062 shares of the company’s stock, valued at $2,333,678.60. The trade was a 13.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 51.98% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on KNSA. Canaccord Genuity Group raised their target price on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Citigroup upped their price target on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. The Goldman Sachs Group increased their price target on Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the stock a “buy” rating in a research note on Wednesday. Weiss Ratings lowered Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c-)” rating in a report on Wednesday. Finally, Wedbush lifted their price objective on Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the stock an “outperform” rating in a report on Wednesday. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $100.57.

Kiniksa Pharmaceuticals International Trading Down 5.5%

KNSA stock opened at $92.24 on Friday. The company’s 50 day moving average is $79.15 and its 200 day moving average is $60.03. The stock has a market cap of $7.20 billion, a price-to-earnings ratio of 70.95 and a beta of 0.04. Kiniksa Pharmaceuticals International, plc has a 1-year low of $36.56 and a 1-year high of $98.48.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. The company had revenue of $285.97 million during the quarter, compared to analyst estimates of $260.66 million. As a group, sell-side analysts forecast that Kiniksa Pharmaceuticals International, plc will post 1.26 EPS for the current fiscal year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.